| Measure | Median (IQR) | p value | ||||
|---|---|---|---|---|---|---|
| Baseline n = 45 | 2 wk n = 39 | 2 mo n = 34 | 4–6 mo n = 31 | Difference between baseline and 4–6 mo n = 31 | ||
| Health-related quality of life | ||||||
| CRQ | 3.5 (2.8 to 4.0) | 4.2 (3.8 to 4.7) | 4.1 (3.6 to 4.8) | 4.2 (3.6 to 4.8) | 0.6 (0.1 to 1.3) | < 0.001 |
| McGill Quality of Life Questionnaire | 5.0 (3.0 to 6.0) | –* | 5.5 (4.0 to 7.5) | 5.0 (5.0 to 7.0) | 1.0 (0 to 2.0) | 0.053 |
| Dyspnea | ||||||
| Numerical rating scale | 7.0 (5.0 to 8.0) | 5.0 (4.0 to 7.0) | 5.0 (4.0 to 6.0) | 5.0 (4.0 to 6.0) | –2.0 (–3.0 to 1.0) | 0.02 |
| CRQ-D | 2.8 (2.3 to 3.6) | 3.9 (3.0 to 4.5) | 3.6 (3.0 to 4.2) | 3.9 (2.8 to 4.5) | 0.6 (0 to 1.4) | 0.004 |
| Anxiety and depression | ||||||
| HADS–Anxiety | 8.0 (6.0 to 10.0) | –* | 7.0 (3.0 to 9.0) | 7.0 (4.0 to 11.0) | –1.5 (–3.0 to 1.0) | 0.2 |
| HADS–Depression | 8.0 (6.0 to 11.0) | –* | 6.0 (4.0 to 8.0) | 7.0 (5.0 to 9.0) | –1.0 (–3.0 to 0.0) | 0.08 |
Note: CRQ = Chronic Respiratory Questionnaire, CRQ-D = dyspnea domain of CRQ, HADS = Hospital Anxiety and Depression Scale, IQR = interquartile range. *Not measured at 2 weeks because we did not anticipate any changes in anxiety or depression at this early stage of opioid therapy.